Lyell Immunopharma (LYEL) Profit After Tax (2020 - 2026)

Lyell Immunopharma has reported Profit After Tax for 7 years, with the latest figure at -$24.4 million in Q1 2026.

• Quarterly Profit After Tax rose 53.24% year-over-year to -$24.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$246.6 million (up 26.14% YoY) and the FY2025 annual result came in at -$274.5 million, up 19.88% from the prior year.
• Profit After Tax advanced to -$24.4 million in Q1 2026 per LYEL's latest filing, from -$140.8 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$6.0 million in Q4 2022 and troughed at -$192.4 million in Q4 2024.
• A 5-year average of -$62.2 million and a median of -$52.2 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax jumped 92.99% in 2022, then slumped 782.17% in 2023.
• Over 5 years, Profit After Tax stood at -$6.0 million in 2022, then slumped by 782.17% to -$52.9 million in 2023, then tumbled by 263.51% to -$192.4 million in 2024, then climbed by 26.84% to -$140.8 million in 2025, then soared by 82.66% to -$24.4 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$24.4 million, -$140.8 million, and -$38.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.